2024/06/13 by Yuxuan Wang, Ran Tao, Yunke Li +4 · 1 voice
Medicine · Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · #Cancer Immunotherapy and Biomarkers #Immune cells in cancer #Single-cell and spatial transcriptomics
paper · pdf · doi:10.18632/aging.205932
openalex publication_date 2024/06/13 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Exploring the molecular mechanisms of PD-1/PDL-1 blockade for non-small cell lung cancer (NSCLC) would facilitate understanding for tumor microenvironment (TME) and development of individualized medicine. To date, biomarkers of response to PD-1 blockade therapy were still limited. In this study, we hypothesize that cell type in the tumor microenvironment can influence the effect of PD-1 blockade immunotherapy through specific genes. Therefore, we re-analyze the single-cell RNA sequencing data and validation in tissue from lung adenocarcinoma patients. Dynamic changes of cellular subpopulation were observed after anti-PD-1 immunotherapy among TMEs between primary/metastasis or good/poor response patients. Non-exhausted CD8 T cells and dysregulated genes were observed in responsing patients from PD-1 blockade therapy. Among all changed genes, JUN, involved in PD-1 blockade immunotherapy pathway, and could be considered as a PD-1 responsing biomarker.